Armata Pharmaceuticals, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Armata submitted its Phase 3 protocol for AP-SA02 (S. aureus bacteremia therapeutic) to the FDA and received Fast Track designation. The company received $2.5 million in non-dilutive funding from the U.S. Department of War (bringing total DoW support to $28.7 million). Q2 2026 cash increased to $24.0 million (from $8.7 million Dec 2025) via $25.0 million term loan and $2.4 million ATM proceeds. Company reported net income of $74.1 million (vs. $16.3 million loss in Q2 2025), driven primarily by a non-cash $91.0 million gain from Convertible Loan fair value change, while core operating loss widened to $10.3 million (vs. $6.8 million). Stockholders' deficit worsened to $(231.2) million.
Why this rating
Phase 3 initiation and FDA Fast Track are meaningful clinical progress for a $21M market-cap biotech. Substantial non-dilutive DoW funding ($28.7M cumulative) materially extends runway. However, widening operating losses, massive stockholder deficit, and $240M+ in debt obligations create existential cash-burn risk despite near-term liquidity.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.